炎症性肠病的药物进展。
Drug advances in inflammatory bowel disease.
机构信息
Department of Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK.
出版信息
Clin Med (Lond). 2013 Aug;13(4):378-82. doi: 10.7861/clinmedicine.13-4-378.
Abstract
The pathogenesis of inflammatory bowel disease (IBD) remains incompletely understood, but is thought to be a consequence of immune dysregulation, impaired mucosal integrity, enteric bacterial dysbiosis and genetic susceptibility factors. Recent drug advances in the treatment of IBD have clarified the role of existing medication, including 5-amino-salicylic acids (5-ASAs) and has seen a burgeoning use of treatment with biologicals. With recent advances in our understanding of these debilitating diseases, it is hoped that novel therapeutic targets can be identified.
摘要
炎症性肠病（IBD）的发病机制尚不完全清楚，但被认为是免疫失调、粘膜完整性受损、肠道细菌失调和遗传易感性因素的结果。最近在治疗 IBD 的药物方面的进展阐明了现有药物（包括 5-氨基水杨酸（5-ASA））的作用，并看到了生物制剂治疗的广泛应用。随着我们对这些使人衰弱的疾病的理解的最新进展，人们希望能确定新的治疗靶点。
相似文献
1
Drug advances in inflammatory bowel disease.炎症性肠病的药物进展。
Clin Med (Lond). 2013 Aug;13(4):378-82. doi: 10.7861/clinmedicine.13-4-378.
2
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.英夫利昔单抗和其他抗肿瘤坏死因子 α 治疗药物治疗炎症性肠病。
BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000.
3
Inflammatory bowel disease and the elderly: a review.炎症性肠病与老年人：综述。
J Crohns Colitis. 2015 Jun;9(6):507-15. doi: 10.1093/ecco-jcc/jjv059. Epub 2015 Apr 13.
4
Immunotherapy in inflammatory bowel disease: Novel and emerging treatments.炎症性肠病的免疫疗法：新出现的治疗方法。
Hum Vaccin Immunother. 2018;14(11):2597-2611. doi: 10.1080/21645515.2018.1461297. Epub 2018 May 22.
5
Immunosuppressive therapies for inflammatory bowel disease.炎症性肠病的免疫抑制疗法。
World J Gastroenterol. 2014 Mar 28;20(12):3146-52. doi: 10.3748/wjg.v20.i12.3146.
6
Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.肠道微生物的代谢功能与炎症性肠病患者肿瘤坏死因子拮抗剂的疗效相关。
Gastroenterology. 2019 Nov;157(5):1279-1292.e11. doi: 10.1053/j.gastro.2019.07.025. Epub 2019 Jul 18.
7
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.抗肿瘤坏死因子α制剂诱导治疗炎症性肠病后粪便钙卫蛋白检测：一年时临床反应和黏膜愈合的预测
Dig Liver Dis. 2014 Nov;46(11):974-9. doi: 10.1016/j.dld.2014.07.013. Epub 2014 Aug 2.
8
Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies.炎症性肠病的生物治疗：超越抗 TNF 治疗。
Clin Immunol. 2019 Sep;206:9-14. doi: 10.1016/j.clim.2018.03.004. Epub 2018 Mar 12.
9
Anti-TNF therapy in inflammatory bowel diseases: a huge review.炎症性肠病中的抗 TNF 治疗：一篇全面综述。
Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43.
10
Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.炎症性肠病患者停用抗TNF药物后的病情演变：一项多中心长期随访研究
Am J Gastroenterol. 2017 Jan;112(1):120-131. doi: 10.1038/ajg.2016.569. Epub 2016 Dec 13.
引用本文的文献
1
Fat and proteolysis due to methionine, tryptophan, and niacin deficiency leads to alterations in gut microbiota and immune modulation in inflammatory bowel disease.由于蛋氨酸、色氨酸和烟酸缺乏导致的脂肪和蛋白质分解，会导致炎症性肠病中的肠道微生物群改变和免疫调节。
Cancer Sci. 2024 Jul;115(7):2473-2485. doi: 10.1111/cas.16153. Epub 2024 Apr 28.
2
Perceptions, behaviours and barriers towards exercise practices in inflammatory bowel disease.炎症性肠病患者对运动实践的认知、行为和障碍。
PLoS One. 2024 Apr 5;19(4):e0299228. doi: 10.1371/journal.pone.0299228. eCollection 2024.
3
Chlorogenic Acid Attenuates Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice through MAPK/ERK/JNK Pathway.绿原酸通过 MAPK/ERK/JNK 通路减轻葡聚糖硫酸钠诱导的小鼠溃疡性结肠炎。
Biomed Res Int. 2019 Apr 18;2019:6769789. doi: 10.1155/2019/6769789. eCollection 2019.
4
Anatomical Road Mapping Using CT and MR Enterography for Ultrasound Molecular Imaging of Small Bowel Inflammation in Swine.使用 CT 和 MR 肠造影术进行解剖学路径映射以进行猪小肠炎症的超声分子成像。
Eur Radiol. 2018 May;28(5):2068-2076. doi: 10.1007/s00330-017-5148-6. Epub 2017 Nov 23.
5
Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy.对于接受英夫利昔单抗治疗一年后停药的炎症性肠病患者，黏膜愈合并不能预测其持续的临床缓解情况。
PLoS One. 2014 Oct 20;9(10):e110797. doi: 10.1371/journal.pone.0110797. eCollection 2014.
6
Worm proteins of Schistosoma mansoni reduce the severity of experimental chronic colitis in mice by suppressing colonic proinflammatory immune responses.曼氏血吸虫的蠕虫蛋白通过抑制结肠促炎免疫反应减轻小鼠实验性慢性结肠炎的严重程度。
PLoS One. 2014 Oct 14;9(10):e110002. doi: 10.1371/journal.pone.0110002. eCollection 2014.
7
Mangiferin attenuates the symptoms of dextran sulfate sodium-induced colitis in mice via NF-κB and MAPK signaling inactivation.芒果苷通过抑制NF-κB和MAPK信号通路减轻葡聚糖硫酸钠诱导的小鼠结肠炎症状。
Int Immunopharmacol. 2014 Nov;23(1):170-8. doi: 10.1016/j.intimp.2014.08.025. Epub 2014 Sep 4.
本文引用的文献
1
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.口服5-氨基水杨酸诱导溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2012 Oct 17;10:CD000543. doi: 10.1002/14651858.CD000543.pub3.
2
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.环孢素与英夫利昔单抗治疗对静脉用类固醇无效的重度溃疡性结肠炎患者的疗效比较：一项平行、开放标签、随机对照试验。
Lancet. 2012 Dec 1;380(9857):1909-15. doi: 10.1016/S0140-6736(12)61084-8. Epub 2012 Oct 10.
3
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.阿达木单抗：来自全球类风湿关节炎、幼年特发性关节炎、强直性脊柱炎、银屑病关节炎、银屑病和克罗恩病临床试验的 23458 例患者的长期安全性。
Ann Rheum Dis. 2013 Apr;72(4):517-24. doi: 10.1136/annrheumdis-2011-201244. Epub 2012 May 5.
4
New therapies for inflammatory bowel disease: from the bench to the bedside.炎症性肠病的新疗法：从实验室到临床。
Gut. 2012 Jun;61(6):918-32. doi: 10.1136/gutjnl-2011-300904. Epub 2011 Nov 23.
5
Development of the Crohn's disease digestive damage score, the Lémann score.克罗恩病消化道损伤评分（Lémann 评分）的制定。
Inflamm Bowel Dis. 2011 Jun;17(6):1415-22. doi: 10.1002/ibd.21506. Epub 2010 Nov 28.
6
A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.炎症性肠病患者发生肝脾 T 细胞淋巴瘤的相关因素的系统评价。
Clin Gastroenterol Hepatol. 2011 Jan;9(1):36-41.e1. doi: 10.1016/j.cgh.2010.09.016. Epub 2010 Oct 1.
7
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies.英国风湿病学会（BSR）和英国风湿病专业注册医师协会（BHPR）关于抗TNF治疗安全性的类风湿关节炎指南。
Rheumatology (Oxford). 2010 Nov;49(11):2217-9. doi: 10.1093/rheumatology/keq249a. Epub 2010 Sep 12.
8
Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates.卡迪夫基于人群队列的克罗恩病自然史（1986-2003 年）：医疗处理和手术切除率变化的研究。
Gut. 2010 Sep;59(9):1200-6. doi: 10.1136/gut.2009.202101. Epub 2010 Jul 21.
9
Infliximab, azathioprine, or combination therapy for Crohn's disease.英夫利昔单抗、硫唑嘌呤或联合治疗克罗恩病。
N Engl J Med. 2010 Apr 15;362(15):1383-95. doi: 10.1056/NEJMoa0904492.
10
The natural history of adult Crohn's disease in population-based cohorts.基于人群队列的成人克罗恩病的自然史。
Am J Gastroenterol. 2010 Feb;105(2):289-97. doi: 10.1038/ajg.2009.579. Epub 2009 Oct 27.
Zotero 插件